4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
INmune Bio Inc. (INMB) operates in the Biotechnology industry and is headquartered in Boca Raton, United States with about 21 employees. Its market capitalization is roughly $47 million. In the fiscal year ended 2025-12-31, INMB reported $0M in revenue and ($46M) in net income.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($31M) | ($43M) | ($30M) | ($26M) |
| Net Income | ($46M) | ($42M) | ($30M) | ($27M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($6M) | ($6M) | ($7M) | ($8M) | ($10M) |
| Net Income | ($5M) | ($5M) | ($6M) | ($24M) | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $32M | $40M | $57M | $82M | — |
| Total Liabilities | $9M | $8M | $19M | $22M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INMB viewer.
About TickerBase · Data methodology & sources